Revenue Breakdown
Composition ()
No data
Revenue Streams
Xtant Medical Holdings Inc (XTNT) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Orthobiologics, accounting for 53.9% of total sales, equivalent to $16.13M. Another important revenue stream is Spinal implant. Understanding this composition is critical for investors evaluating how XTNT navigates market cycles within the Medical Equipment, Supplies & Distribution industry.
Profitability & Margins
Evaluating the bottom line, Xtant Medical Holdings Inc maintains a gross margin of 66.13%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 7.64%, while the net margin is 3.93%. These profitability ratios, combined with a Return on Equity (ROE) of 3.64%, provide a clear picture of how effectively XTNT converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, XTNT competes directly with industry leaders such as WRAP and VANI. With a market capitalization of $86.52M, it holds a leading position in the sector. When comparing efficiency, XTNT's gross margin of 66.13% stands against WRAP's 59.22% and VANI's N/A. Such benchmarking helps identify whether Xtant Medical Holdings Inc is trading at a premium or discount relative to its financial performance.
